Table 6 Selected first-line results from phase 1/2 trials in ROS1 rearranged NSCLC
From: Oncogenic alterations in advanced NSCLC: a molecular super-highway
Trial | Clinical trials ID | Treatments | Objective response rate (%) | Median progression-free survival (months) | Median overall survival (months) |
|---|---|---|---|---|---|
PROFILE-1001 | NCT00585195 | Crizotinib | 72 | 19.3 | NR |
TRIDENT-1 | NCT03093116 | Repotrectinib | 78.9 | NR | NR |
Shaw et al | NCT01970865 | Lorlatinib | 62 | 19.3 | NR |
Pooled analysis of STARTRK-1, STARTRK-2, ALKA-372 | NA | Entrectinib in treatment-naïve patients | 68.7 | 17.7 | 47.7 |